ADVERTISEMENT

Parkinson's disease: antibodies to α-synuclein miss the mark

Susan London   |   Clinical Summary   |   17 August 2022
ADVERTISEMENT

Takeaway

  • The antibodies cinpanemab and prasinezumab, directed against α-synuclein, did not slow the progression of early Parkinson's disease.

Why this matters

  • Aggregated α-synuclein plays an important role in pathogenesis of this disease having limited treatment options.

Key results

  • Change in Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) total score...

          

Topic Challenges

left
right